MarketCap
Perrigo Company plc PRGO
$ 10.43
1.26%
Facebook
X
Telegram
Perrigo Company plc Revenue | PRGO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Perrigo Company plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.25 B | 4.37 B | 4.66 B | 4.45 B | 4.14 B | 4.09 B | 4.84 B | 4.73 B | 4.95 B | 5.28 B | 4.6 B | 4.06 B | 3.54 B | 3.17 B | 2.76 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.28 B | 2.76 B | 4.26 B |
Quarterly Revenue Perrigo Company plc
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 969 M | 1.04 B | 1.06 B | 1.04 B | - | 1.09 B | 1.07 B | 1.08 B | - | 1.12 B | 1.19 B | 1.18 B | - | 1.1 B | 1.12 B | 1.07 B | - | 1.04 B | 981 M | 1.01 B | 1.29 B | 1.21 B | 1.22 B | 1.34 B | 1.32 B | 1.19 B | 1.15 B | 1.17 B | 1.2 B | 1.13 B | 1.19 B | 1.22 B | 1.28 B | 1.23 B | 1.24 B | 1.19 B | 1.33 B | 1.26 B | 1.34 B | 1.35 B | 1.36 B | 1.34 B | 1.53 B | 1.34 B | 985 M | 860 M | 1.07 B | 952 M | 979 M | 933 M | 979 M | - | 883 M | 770 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.53 B | 770 M | 1.14 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ProPhase Labs
PRPH
|
4.34 M | - | - | $ 5.07 M |  USA |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
10.2 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
874 K | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
28 K | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
2.03 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | USA |
 |
OrganiGram Holdings
OGI
|
160 M | $ 0.93 | -1.97 % | $ 88.6 M | Canada |
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
19.5 M | $ 1.1 | -3.51 % | $ 1.85 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
Cronos Group
CRON
|
147 M | $ 2.86 | 0.35 % | $ 1.1 B | Canada |
 |
Veru
VERU
|
16.9 M | $ 2.21 | -0.9 % | $ 32.4 M | USA |
 |
Jupiter Wellness
JUPW
|
2.12 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
Canopy Growth Corporation
CGC
|
285 M | $ 0.89 | -0.53 % | $ 265 M | Canada |
 |
cbdMD
YCBD
|
19.2 M | $ 0.49 | -2.2 % | $ 1.97 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
13.7 M | $ 6.66 | -2.2 % | $ 98.9 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
925 K | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
119 M | - | - | $ 150 M | USA |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
78.2 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
86 K | - | - | $ 55.5 M | USA |
 |
Zomedica Corp.
ZOM
|
32 M | - | -0.21 % | $ 98 M | USA |
 |
Bausch Health Companies
BHC
|
10.3 B | $ 4.68 | 3.43 % | $ 1.74 B | Canada |
 |
Emergent BioSolutions
EBS
|
743 M | $ 7.35 | 0.55 % | $ 393 M | USA |
 |
China Pharma Holdings
CPHI
|
4.14 M | $ 1.2 | -8.4 % | $ 5.15 M |  China |
 |
Aurora Cannabis
ACB
|
175 M | $ 2.73 | 0.37 % | $ 150 M | Canada |
 |
Harrow Health
HROW
|
272 M | $ 38.68 | -1.63 % | $ 1.42 B | USA |
 |
Evolus
EOLS
|
297 M | $ 6.03 | -3.05 % | $ 389 M | USA |
 |
Rockwell Medical
RMTI
|
69.3 M | $ 6.88 | -1.57 % | $ 248 M | USA |
 |
SCYNEXIS
SCYX
|
20.6 M | $ 3.77 | 3.43 % | $ 188 M | USA |
 |
Solid Biosciences
SLDB
|
8.09 M | $ 8.04 | 0.88 % | $ 704 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 5.14 | -1.72 % | $ 203 M | USA |
 |
Organogenesis Holdings
ORGO
|
564 M | $ 2.52 | -0.4 % | $ 319 M | USA |
 |
Pacira BioSciences
PCRX
|
542 M | $ 26.4 | -1.53 % | $ 1.22 B | USA |
 |
TherapeuticsMD
TXMD
|
3.02 M | $ 2.06 | - | $ 23.8 M | USA |
 |
Sundial Growers
SNDL
|
946 M | $ 1.2 | -1.64 % | $ 310 M | Canada |
 |
Tilray
TLRY
|
821 M | $ 3.99 | -0.99 % | $ 3.55 B | Canada |